We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > cilta-cel

News List

Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen AmericanPharmaceuticalReview
February 15, 2022
Legend Biotech Corporation has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel)...
Janssen’s myeloma CAR T therapy cilta-cel demonstrates ‘sustained efficacy’ pharmatimes
June 03, 2021
Janssen has reported new data for its B-cell maturation antigen (BCMA) directed CAR T therapy ciltacabtagene autoleucel (cilta-cel) in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients.
J&J, Legend's CAR-T therapy cilta-cel granted priority review by FDA firstwordpharma
May 27, 2021
The FDA has accepted a marketing application for Johnson & Johnson and partner Legend Biotech's BCMA-directed CAR-T therapy ciltacabtagene autoleucel (cilta-cel) for priority review as a potential treatment of adults with relapsed and/or refractory
Janssen seeks EU approval for first CAR-T therapy cilta-cel pharmatimes
May 07, 2021
Johnson & Johnson’s (J&J) pharma division Janssen has filed its first CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) with the European Medicines Agency (EMA), seeking approval for the treatment of patients with relapsed/refractory multiple ...